<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830842</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00043890</org_study_id>
    <nct_id>NCT01830842</nct_id>
  </id_info>
  <brief_title>Acute and Chronic Nicotine Modulation of Reinforcement Learning</brief_title>
  <acronym>NicLearning</acronym>
  <official_title>Acute and Chronic Nicotine Modulation of Reinforcement Learning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use functional magnetic resonance imaging (fMRI) to
      investigate the acute and chronic effects of nicotine on motivational behavior and prediction
      error-related neural activation. Nonsmokers (n = 24) and smokers (n = 24) will undergo fMRI
      scans on two separate occasions while performing a decision-making task that will elicit
      prediction error signals in the mesocorticolimbic pathway of the brain. Nonsmokers will be
      scanned once following an acute dose of nicotine and once following placebo administration.
      Smokers will be scanned once following smoking as usual and once following 24-hours of
      smoking abstinence, in order to measure the effects of nicotine withdrawal. The study team
      hypothesizes that acute nicotine will increase the prediction error signal in nonsmokers
      compared to placebo, and that nicotine withdrawal will decrease the prediction error signal
      in smokers compared to the normal satiated condition. Furthermore, nonsmokers (during the
      placebo condition) will have greater prediction error activation than smokers (during the
      satiated condition). The results of this study will inform whether the initiation and
      maintenance of smoking behavior could be facilitated by the effects of nicotine on
      reinforcement learning.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood Oxygen Level Dependent (BOLD) Signal in Dorsomedial Prefrontal Cortex</measure>
    <time_frame>Nonsmokers: post nicotine and post placebo. Smokers: 24 hours smoking abstinence or smoking satiety</time_frame>
    <description>The acute and chronic effects of nicotine on the blood oxygen level dependent signal will be measured using functional magnetic resonance imaging. Reward-cue related BOLD signal on an outcome expectation task.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Nicotine Addiction</condition>
  <arm_group>
    <arm_group_label>Nicotine, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine withdrawal or satiety</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine polacrilex</intervention_name>
    <description>nonsmokers will be measured following nicotine administration</description>
    <arm_group_label>Nicotine, placebo</arm_group_label>
    <other_name>nicotine condition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>nonsmokers will be measured following placebo administration</description>
    <arm_group_label>Nicotine, placebo</arm_group_label>
    <other_name>placebo condition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>satiety</intervention_name>
    <description>smokers will be measured in a smoking satiated condition</description>
    <arm_group_label>Nicotine withdrawal or satiety</arm_group_label>
    <other_name>smoking satiated condition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>abstinence</intervention_name>
    <description>smokers will be measured following 24-hours of smoking abstinence</description>
    <arm_group_label>Nicotine withdrawal or satiety</arm_group_label>
    <other_name>smoking abstinence condition</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria for all subjects:

          1. generally healthy

          2. between the ages of 18-55

          3. right-handed

        Inclusion criteria for nonsmokers:

          1. smoked &lt; 50 cigarettes of a brand delivering ≥ 0.5 mg nicotine (FTC method)

          2. have not smoked in ≥ 6 months

          3. afternoon expired CO concentration ≤ 5 ppm and/or morning urinary NicAlert &lt; 100 ng/ml

        Inclusion criteria for smokers

          1. smoke ≥ 10 cigarettes/day of a brand delivering ≥ 0.5 mg nicotine (FTC method)

          2. smoked ≥ 2 years

          3. afternoon expired CO concentrations ≥ 10 ppm and/or morning urinary NicAlert &gt; 100
             ng/ml

        Exclusion Criteria:

          1. inability to attend all required experimental sessions

          2. significant health problems (e.g., current and uncontrolled liver, lung, or heart
             problems, current or past seizure disorder, serious head trauma)

          3. lifetime diagnosis of Axis I psychiatric disorders (e.g., depression, anxiety
             disorder, schizophrenia)

          4. meet DSM-V criteria for past or current substance dependence other than nicotine

          5. use of psychoactive medications as indicated by self-report

          6. use of smokeless tobacco, nicotine replacement therapy, or desire to change smoking
             behavior while in the study

          7. positive urine drug screen for illicit drugs or positive breath alcohol concentration

          8. presence of conditions that would make MRI unsafe

          9. having vision that cannot be corrected to 20/40

         10. among women, nursing or a positive pregnancy test

         11. inability to achieve learning criteria in training session
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merideth A Addicott, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <results_first_submitted>October 16, 2017</results_first_submitted>
  <results_first_submitted_qc>November 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2017</results_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine</keyword>
  <keyword>Smoking</keyword>
  <keyword>Cigarettes</keyword>
  <keyword>Reinforcement Learning</keyword>
  <keyword>fMRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nicotine, Placebo</title>
          <description>Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
Nicotine polacrilex: nonsmokers will be measured following nicotine administration
Placebo: nonsmokers will be measured following placebo administration</description>
        </group>
        <group group_id="P2">
          <title>Nicotine Withdrawal or Satiety</title>
          <description>Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
satiety: smokers will be measured in a smoking satiated condition
abstinence: smokers will be measured following 24-hours of smoking abstinence</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nicotine, Placebo</title>
          <description>Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
Nicotine polacrilex: nonsmokers will be measured following nicotine administration
Placebo: nonsmokers will be measured following placebo administration</description>
        </group>
        <group group_id="B2">
          <title>Nicotine Withdrawal or Satiety</title>
          <description>Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
satiety: smokers will be measured in a smoking satiated condition
abstinence: smokers will be measured following 24-hours of smoking abstinence</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="11"/>
                    <measurement group_id="B2" value="35" spread="10"/>
                    <measurement group_id="B3" value="34" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Blood Oxygen Level Dependent (BOLD) Signal in Dorsomedial Prefrontal Cortex</title>
        <description>The acute and chronic effects of nicotine on the blood oxygen level dependent signal will be measured using functional magnetic resonance imaging. Reward-cue related BOLD signal on an outcome expectation task.</description>
        <time_frame>Nonsmokers: post nicotine and post placebo. Smokers: 24 hours smoking abstinence or smoking satiety</time_frame>
        <population>Subjects who did not follow MRI task instructions, or those with &gt; 3 mm of movement, were excluded from the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Nonsmokers</title>
            <description>Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
Nicotine polacrilex: nonsmokers will be measured following nicotine administration
Placebo: nonsmokers will be measured following placebo administration</description>
          </group>
          <group group_id="O2">
            <title>Smokers</title>
            <description>Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
satiety: smokers will be measured in a smoking satiated condition
abstinence: smokers will be measured following 24-hours of smoking abstinence</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Oxygen Level Dependent (BOLD) Signal in Dorsomedial Prefrontal Cortex</title>
          <description>The acute and chronic effects of nicotine on the blood oxygen level dependent signal will be measured using functional magnetic resonance imaging. Reward-cue related BOLD signal on an outcome expectation task.</description>
          <population>Subjects who did not follow MRI task instructions, or those with &gt; 3 mm of movement, were excluded from the analyses.</population>
          <units>percentage of BOLD signal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nicotine or satiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="15"/>
                    <measurement group_id="O2" value="6.3" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo or abstinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="12"/>
                    <measurement group_id="O2" value=".02" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nicotine, Placebo</title>
          <description>Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
Nicotine polacrilex: nonsmokers will be measured following nicotine administration
Placebo: nonsmokers will be measured following placebo administration</description>
        </group>
        <group group_id="E2">
          <title>Nicotine Withdrawal or Satiety</title>
          <description>Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
satiety: smokers will be measured in a smoking satiated condition
abstinence: smokers will be measured following 24-hours of smoking abstinence</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merideth Addicott</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-526-8436 ext 501</phone>
      <email>MAddicott@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

